A Phase Ib Study of ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed Chronic Lymphocytic Leukemia

Next Previous
Trial Profile

A Phase Ib Study of ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed Chronic Lymphocytic Leukemia

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Jun 2017

At a glance

  • Drugs Ibrutinib (Primary) ; Idelalisib (Primary) ; Ricolinostat (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions

    • Most Recent Events

    • 25 May 2017 Status changed from recruiting to active, no longer recruiting.
    • 16 Nov 2016 Status changed from not yet recruiting to recruiting.
    • 04 Jun 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top